Altimmune, Inc.
ALTHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeAltimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Valued at $558.1M, ALT is a small-cap name in its sector. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Market Cap
$558.1M
Beta
0.24
P/E (TTM)
—
P/E (Fwd)
-3.34
EPS (TTM)
$-0.92
EPS (Fwd)
$-0.86
ROE
-42.8%
ROA
-24.4%
Cash
$331.5M
Total Debt
$35.8M
Free CF
-$42.5M
52W Change
-29.7%
Annual Financials
Cash vs Debt
Altimmune, Inc. holds $331.5M in cash against $35.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$42.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -42.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from -$68K (2022) to $41K (2025), reflecting a 160% increase over the period.
The relatively low beta of 0.24 suggests ALT is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ALT.